Petr Alexandrovich Baranov
Research Subjects
Petr Alexandrovich Baranov has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Igor V. Oleichik
Mental Health Research Center
16 shared publications - Stepan V. Sizov
Mental Health Research Center
5 shared publications - T. I. Shishkovskaia
Mental Health Research Center
5 shared publications - Elena Georgievna Starostina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
4 shared publications - O. A. Yunilaynen
Centre for Mental Health Research
3 shared publications - Alexandra Sergeevna Moreva
Mental Health Research Center
2 shared publications
Latest Publications
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
The association between blood enzyme activity in patients with depression and delusional disorders and their response to psychopharmacotherapy
Objective. To identify biochemical parameters correlated with the characteristics of the clinical response to psychopharmacotherapy (PFT) in patients with depressive-delusional states of various nosological origins. Material and methods. This study included 54 patients, aged 18 to 52 years, diagnosed with depression and delusional disorders across various nosological categories (F20.02; F25.1; F31.5 according to ICD-10). Scores were obtained using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HAM-D), both administered before and after PPT. Prior to initiating treatment, the activity of enzymes involved in energy metabolism, glutamate metabolism, and antioxidant/glutathione metabolism in platelets and red blood cells was measured. Results. The patient population was segmented into two distinct diagnostic subgroups: schizophrenia spectrum disorders (SSD; F20.02; F25.1; n=34) and affective spectrum disorders (F31.5; n=21). Biochemical parameters were identified within these subgroups that correlated with reductions in PANSS (redPANSS) and HAM-D scores, as well as with scores on these scales following completion of the PPT (PANSS2). In the subgroup with affective disorders, significant correlations were observed between creatine phosphokinase (CPK) activity and redPANSS-Neg (R=0.47, p=0.02), as well as with PANSS-Neg2 (R=–0.52, p=0.01); glutamate dehydrogenase activity also correlated with PANSS-Pos2 (R=–0.48, p=0.01). In the SSD subgroup, correlations were found between CPK and glutathione S-transferase (GST) activity and redPANSS-Pos (R=0.38 and R=0.44, p<0.03). Furthermore, within two distinct patient clusters (n=29 and n=26) identified by biochemical characteristics, notable correlations were observed: in the larger cluster, the CPK activity correlated with redPANSS-Tot, redPANSS-Pos, redPANSS-Neg, and PANSS-Tot2 (R=0.47, R=0.53, R=0.43, R=–0.47, p<0.02); in the smaller cluster, a correlation was identified between the red blood cell GST activity and redPANSS-Neg (R=0.46, p=0.02). Conclusion. The identified significant correlations between biochemical parameters and the degree of reduction in the total score on psychometric scales after the course of therapy make it possible to use these potential candidates as biomarkers in clinical practice to predict the effectiveness of PFT.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
The association between blood enzyme activity in patients with depression and delusional disorders and their response to psychopharmacotherapy
Objective. To identify biochemical parameters correlated with the characteristics of the clinical response to psychopharmacotherapy (PFT) in patients with depressive-delusional states of various nosological origins. Material and methods. This study included 54 patients, aged 18 to 52 years, diagnosed with depression and delusional disorders across various nosological categories (F20.02; F25.1; F31.5 according to ICD-10). Scores were obtained using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale (HAM-D), both administered before and after PPT. Prior to initiating treatment, the activity of enzymes involved in energy metabolism, glutamate metabolism, and antioxidant/glutathione metabolism in platelets and red blood cells was measured. Results. The patient population was segmented into two distinct diagnostic subgroups: schizophrenia spectrum disorders (SSD; F20.02; F25.1; n=34) and affective spectrum disorders (F31.5; n=21). Biochemical parameters were identified within these subgroups that correlated with reductions in PANSS (redPANSS) and HAM-D scores, as well as with scores on these scales following completion of the PPT (PANSS2). In the subgroup with affective disorders, significant correlations were observed between creatine phosphokinase (CPK) activity and redPANSS-Neg (R=0.47, p=0.02), as well as with PANSS-Neg2 (R=–0.52, p=0.01); glutamate dehydrogenase activity also correlated with PANSS-Pos2 (R=–0.48, p=0.01). In the SSD subgroup, correlations were found between CPK and glutathione S-transferase (GST) activity and redPANSS-Pos (R=0.38 and R=0.44, p<0.03). Furthermore, within two distinct patient clusters (n=29 and n=26) identified by biochemical characteristics, notable correlations were observed: in the larger cluster, the CPK activity correlated with redPANSS-Tot, redPANSS-Pos, redPANSS-Neg, and PANSS-Tot2 (R=0.47, R=0.53, R=0.43, R=–0.47, p<0.02); in the smaller cluster, a correlation was identified between the red blood cell GST activity and redPANSS-Neg (R=0.46, p=0.02). Conclusion. The identified significant correlations between biochemical parameters and the degree of reduction in the total score on psychometric scales after the course of therapy make it possible to use these potential candidates as biomarkers in clinical practice to predict the effectiveness of PFT.
- 3 June 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (2)
Hyperprolactinemia, Induced by Antipsychotics and Resistant to Cabergoline Therapy
Background : hyperprolactinemia is common in patients with mental disorders receiving antipsychotics. Cabergoline therapy for normalizing prolactin in these patients has been found to be effective. Cases of prolactin-secreting pituitary adenomas resistant to cabergoline have been described in the literature. Clinical observations of antipsychotic-induced/antipsychoticassociated hyperprolactinemia resistant to cabergoline therapy are rare in scientific publications. The aim of the study was to describe clinical cases and justify treatment approaches to hyperprolactinemia, associated with antipsychotics and resistant to cabergoline therapy. Patients and Methods : the study involved female patients with endogenous mental disorders undergoing inpatient treatment. Clinical, psychopathological, and laboratory examination methods were used. Case description: Case 1 — a 23-year-old female, mentally ill since the age of 17, was twice treated in mental hospitals for a depressive state within the framework of schizotypal disorder. A severe course of depression with a high risk of suicide and clear resistance to drug therapy was noted; a course of ECT was administered. The therapeutic effect was achieved through the use of antipsychotics, but an increase in prolactin levels was detected. Hyperprolactinemia was accompanied by weight gain, lactorrhea, and hair loss. Cabergoline at a dose of 3.5 mg per week was ineffective. With the correction of antipsychotic therapy, the level of prolactin in the blood returned to normal. Case 2 — a 37-year-old female, mentally ill since the age of 19, was repeatedly treated in mental hospitals for hallucinatory-delusional symptoms. Chronicity of the disease and pronounced resistance to drug treatment were noted. A course of ECT was administered to overcome resistance. Prescription of antipsychotics resulted in a significant reduction in hallucinatory-delusional symptoms and improvement in the patient's quality of life; however, the development of hyperprolactinemia was detected. Cabergoline at a dose of 3.5 mg per week was ineffective. Hyperprolactinemia was virtually asymptomatic (including the absence of hypogonadism), cabergoline was terminated, and psychopharmacotherapy was continued according to the previous treatment regimen. Conclusion : if cabergoline 3.0 mg/week is ineffective, antipsychotic-induced/ antipsychotic-associated hyperprolactinemia may be considered cabergoline-resistant. The choice of treatment tactics in this case should be carried out individually, taking into account the clinical manifestations of hyperprolactinemia, a comprehensive analysis of laboratory parameters, and the specificities of the course of the mental disorder.
- 3 June 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (2)
Hyperprolactinemia, Induced by Antipsychotics and Resistant to Cabergoline Therapy
Background : hyperprolactinemia is common in patients with mental disorders receiving antipsychotics. Cabergoline therapy for normalizing prolactin in these patients has been found to be effective. Cases of prolactin-secreting pituitary adenomas resistant to cabergoline have been described in the literature. Clinical observations of antipsychotic-induced/antipsychoticassociated hyperprolactinemia resistant to cabergoline therapy are rare in scientific publications. The aim of the study was to describe clinical cases and justify treatment approaches to hyperprolactinemia, associated with antipsychotics and resistant to cabergoline therapy. Patients and Methods : the study involved female patients with endogenous mental disorders undergoing inpatient treatment. Clinical, psychopathological, and laboratory examination methods were used. Case description: Case 1 — a 23-year-old female, mentally ill since the age of 17, was twice treated in mental hospitals for a depressive state within the framework of schizotypal disorder. A severe course of depression with a high risk of suicide and clear resistance to drug therapy was noted; a course of ECT was administered. The therapeutic effect was achieved through the use of antipsychotics, but an increase in prolactin levels was detected. Hyperprolactinemia was accompanied by weight gain, lactorrhea, and hair loss. Cabergoline at a dose of 3.5 mg per week was ineffective. With the correction of antipsychotic therapy, the level of prolactin in the blood returned to normal. Case 2 — a 37-year-old female, mentally ill since the age of 19, was repeatedly treated in mental hospitals for hallucinatory-delusional symptoms. Chronicity of the disease and pronounced resistance to drug treatment were noted. A course of ECT was administered to overcome resistance. Prescription of antipsychotics resulted in a significant reduction in hallucinatory-delusional symptoms and improvement in the patient's quality of life; however, the development of hyperprolactinemia was detected. Cabergoline at a dose of 3.5 mg per week was ineffective. Hyperprolactinemia was virtually asymptomatic (including the absence of hypogonadism), cabergoline was terminated, and psychopharmacotherapy was continued according to the previous treatment regimen. Conclusion : if cabergoline 3.0 mg/week is ineffective, antipsychotic-induced/ antipsychotic-associated hyperprolactinemia may be considered cabergoline-resistant. The choice of treatment tactics in this case should be carried out individually, taking into account the clinical manifestations of hyperprolactinemia, a comprehensive analysis of laboratory parameters, and the specificities of the course of the mental disorder.
- 27 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (6) , 45-54
Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients
Objective. To study the association of cortisol level, clinical features of depression, its nosological type, and the therapeutic response in female patients. Material and methods. 69 females aged 18 to 50 were examined; clinical-psychopathological, clinical-prospective, psychometric, laboratory, and statistical methods were used. Results. 17 patients were included in the group with depression without signs of resistance, and 52 in the group of therapeutically resistant depression (TRD). Hypercortisolemia at baseline was observed in 23% of patients, and hypocortisolemia in 6%. The absence of cortisol inhibition in a low-dose dexamethasone suppression test (LDDST) was found in 42% of patients. Patients with hypercortisolemia were more likely to be diagnosed with paroxysmal schizophrenia compared to patients with normal cortisol: 3/16 (19%) vs. 1/49 (2%), respectively (p=0.043). There were no differences in the clinical and psychopathological structure of depression and its formal severity in patients with hypercortisolemia and normal cortisol levels. In psychometric assessment, patients with hypercortisolemia had significantly higher scores of psychomotor retardation (HAMD, case report form) than those with normal cortisol levels (p=0.009). In the group with negative LDDST, significantly higher agitation (p=0.045) and adynamia (p=0.017) scores were found than those with positive LDDST. In patients with abnormal circadian rhythm of cortisol secretion, significantly higher anhedonia scores were noted than in patients with normal daily cortisol secretion (p=0.02). The state of patients with negative LDDST was significantly worse at follow-up examination than in those with positive LDDST (p=0.04). In patients with a good response to treatment, the cortisol level in LDDST upon repeated examination was significantly lower than in non-curable patients: 34.1 [22.8—65.3] and 80.2 [66.8—120.8] nmol/L, respectively (p=0.02). Conclusions. In patients with depression, the prevalence of hypothalamic-pituitary-adrenal (HPA) axis dysfunction is higher than in the general population. HPA axis dysfunction appears to be associated with psychomotor retardation, adynamia, agitation, and anhedonia. The lack of cortisol inhibition in LDDST is the most reliable laboratory marker of a low-curable depressive state. Absolute treatment resistance in depression is associated with HPA axis dysfunction.
- 27 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (6) , 45-54
Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients
Objective. To study the association of cortisol level, clinical features of depression, its nosological type, and the therapeutic response in female patients. Material and methods. 69 females aged 18 to 50 were examined; clinical-psychopathological, clinical-prospective, psychometric, laboratory, and statistical methods were used. Results. 17 patients were included in the group with depression without signs of resistance, and 52 in the group of therapeutically resistant depression (TRD). Hypercortisolemia at baseline was observed in 23% of patients, and hypocortisolemia in 6%. The absence of cortisol inhibition in a low-dose dexamethasone suppression test (LDDST) was found in 42% of patients. Patients with hypercortisolemia were more likely to be diagnosed with paroxysmal schizophrenia compared to patients with normal cortisol: 3/16 (19%) vs. 1/49 (2%), respectively (p=0.043). There were no differences in the clinical and psychopathological structure of depression and its formal severity in patients with hypercortisolemia and normal cortisol levels. In psychometric assessment, patients with hypercortisolemia had significantly higher scores of psychomotor retardation (HAMD, case report form) than those with normal cortisol levels (p=0.009). In the group with negative LDDST, significantly higher agitation (p=0.045) and adynamia (p=0.017) scores were found than those with positive LDDST. In patients with abnormal circadian rhythm of cortisol secretion, significantly higher anhedonia scores were noted than in patients with normal daily cortisol secretion (p=0.02). The state of patients with negative LDDST was significantly worse at follow-up examination than in those with positive LDDST (p=0.04). In patients with a good response to treatment, the cortisol level in LDDST upon repeated examination was significantly lower than in non-curable patients: 34.1 [22.8—65.3] and 80.2 [66.8—120.8] nmol/L, respectively (p=0.02). Conclusions. In patients with depression, the prevalence of hypothalamic-pituitary-adrenal (HPA) axis dysfunction is higher than in the general population. HPA axis dysfunction appears to be associated with psychomotor retardation, adynamia, agitation, and anhedonia. The lack of cortisol inhibition in LDDST is the most reliable laboratory marker of a low-curable depressive state. Absolute treatment resistance in depression is associated with HPA axis dysfunction.
- Open Access
- 17 December 2024
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 6 (4) , 324-335
Neuropsychological and personality traits of adolescent and young adult female patients with depression accompanied by non-suicidal auto-aggression: basis for psychotherapy and neurorehabilitation strategies
BACKGROUND: Depression is often accompanied by cognitive impairments leading to maladaptation, decreased performance, reduced quality of life, and auto-aggression. Thus, it is required to study their basis to develop special therapeutic programs. AIM: This study identifies the cognitive profile and personality traits of adolescent and young adult patients with depression accompanied by non-suicidal self-harming behavior (NSSHB) as a basis for a neurorehabilitation and psychotherapy program. METHODS: The study included 50 female patients aged 16–25 (mean age 19±2.2) with various types of depression (F31.3–4; F34.0; F21.3-4+F31.3–4; F60.X+F31.3–4), accompanied by NSSHB (study group). Neuropsychological assessments were conducted using Luria’s neuropsychological battery. The study also involved a personality assessment of patients using a clinical interview and psychometrics. The control group included 50 females aged 16–25 (mean age 18±1.4). Psychometrics included the Interpersonal Needs Questionnaire (INQ) and the Deviant Behavior Manifestations Questionnaire (H-h). Moreover, this part of the study used Fear of Pain Questionnaire (FPQ-SF) and Pain Catastrophizing Scale (PCS) as an additional tool to assess possible correlations. RESULTS: The study showed that young female patients with depression and NSSHB had a number of neuropsychological and personality traits, including impaired voluntary emotion regulation and reduced cognitive flexibility. These are potential factors of behavioral deviations leading to maladaptation. The findings indicate the need for a comprehensive approach to rehabilitation of individuals with depressive disorders, integrating neuropsychological techniques and psychotherapy. Special support programs help reduce anxiety and have a positive effect on the patient’s cognition and quality of life. Further research into the integration of these strategies and their long-term impact is suggested, as they may form the basis for more effective non-pharmacological treatments for mental health disorders. CONCLUSION: The findings suggest specific cognitive traits in adolescent and young adult patients with various types of depression accompanied by NSSHB. For higher functions, patients show significant impairment in executive functions, regulatory control, thought process neurodynamics, and general mental activity. The severity of symptoms and their combination may be considered in the context of a specific cognitive and personality profile of this group of patients. Basic neurorehabilitation principles and psychotherapy strategies for such patients were developed based on the collected data.
- 17 December 2024
- Published by Federal Research and Clinical Center for Resuscitation and Rehabilitation in Physical and rehabilitation medicine, medical rehabilitation
- Vol. 6 (4) , 324-335
Open AccessNeuropsychological and personality traits of adolescent and young adult female patients with depression accompanied by non-suicidal auto-aggression: basis for psychotherapy and neurorehabilitation strategies
BACKGROUND: Depression is often accompanied by cognitive impairments leading to maladaptation, decreased performance, reduced quality of life, and auto-aggression. Thus, it is required to study their basis to develop special therapeutic programs. AIM: This study identifies the cognitive profile and personality traits of adolescent and young adult patients with depression accompanied by non-suicidal self-harming behavior (NSSHB) as a basis for a neurorehabilitation and psychotherapy program. METHODS: The study included 50 female patients aged 16–25 (mean age 19±2.2) with various types of depression (F31.3–4; F34.0; F21.3-4+F31.3–4; F60.X+F31.3–4), accompanied by NSSHB (study group). Neuropsychological assessments were conducted using Luria’s neuropsychological battery. The study also involved a personality assessment of patients using a clinical interview and psychometrics. The control group included 50 females aged 16–25 (mean age 18±1.4). Psychometrics included the Interpersonal Needs Questionnaire (INQ) and the Deviant Behavior Manifestations Questionnaire (H-h). Moreover, this part of the study used Fear of Pain Questionnaire (FPQ-SF) and Pain Catastrophizing Scale (PCS) as an additional tool to assess possible correlations. RESULTS: The study showed that young female patients with depression and NSSHB had a number of neuropsychological and personality traits, including impaired voluntary emotion regulation and reduced cognitive flexibility. These are potential factors of behavioral deviations leading to maladaptation. The findings indicate the need for a comprehensive approach to rehabilitation of individuals with depressive disorders, integrating neuropsychological techniques and psychotherapy. Special support programs help reduce anxiety and have a positive effect on the patient’s cognition and quality of life. Further research into the integration of these strategies and their long-term impact is suggested, as they may form the basis for more effective non-pharmacological treatments for mental health disorders. CONCLUSION: The findings suggest specific cognitive traits in adolescent and young adult patients with various types of depression accompanied by NSSHB. For higher functions, patients show significant impairment in executive functions, regulatory control, thought process neurodynamics, and general mental activity. The severity of symptoms and their combination may be considered in the context of a specific cognitive and personality profile of this group of patients. Basic neurorehabilitation principles and psychotherapy strategies for such patients were developed based on the collected data.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 75-81
Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic)
Objective. A clinical and psychopathological analysis, nosological differentiation of prolonged and chronic manic and manic-delusional states (PMDS) within the framework of the paroxysmal course of endogenous psychoses, determination of the patterns of their development, diagnostic criteria and prognosis. Material and methods. The study included 76 female patients (average age 37.2±8.3 years) who were hospitalized for endogenous mental illnesses with a paroxysmal course that occurred with the clinical picture of PMDS. The patients were divided into two groups: clinical (n=43) and follow-up (n=33). Clinical-psychopathological, clinical-follow-up, psychometric, statistical methods were used. Results. A clinical and dynamic typology of PMDS has been developed, according to which 2 groups have been identified: «monomorphic» PMDS and «polymorphic» PMDS. «Monomorphic» PMDS included 2 subtypes — «acute» and «chronified» and were characterized by the same clinical picture that remained unchanged throughout, while «polymorphic», which also included 2 subtypes — «developing» and «double mania subtype», were characterized by the variability of clinical picture. «Acute» and «developing» subtypes of PMDS predominantly developed in schizoaffective psychosis and bipolar disorder; the «chronified» subtype and the «double mania» subtype were more often observed within the framework of the schizoaffective variant of paroxysmal-progressive schizophrenia. Conclusion. The clinical and dynamic structure of PMDS is heterogeneous and differs in psychopathological structure, as well as in the level of stability of symptoms and characteristics of its course. The developed clinical typology of PMDS is prognostically significant and provides information about the further dynamics of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 75-81
Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic)
Objective. A clinical and psychopathological analysis, nosological differentiation of prolonged and chronic manic and manic-delusional states (PMDS) within the framework of the paroxysmal course of endogenous psychoses, determination of the patterns of their development, diagnostic criteria and prognosis. Material and methods. The study included 76 female patients (average age 37.2±8.3 years) who were hospitalized for endogenous mental illnesses with a paroxysmal course that occurred with the clinical picture of PMDS. The patients were divided into two groups: clinical (n=43) and follow-up (n=33). Clinical-psychopathological, clinical-follow-up, psychometric, statistical methods were used. Results. A clinical and dynamic typology of PMDS has been developed, according to which 2 groups have been identified: «monomorphic» PMDS and «polymorphic» PMDS. «Monomorphic» PMDS included 2 subtypes — «acute» and «chronified» and were characterized by the same clinical picture that remained unchanged throughout, while «polymorphic», which also included 2 subtypes — «developing» and «double mania subtype», were characterized by the variability of clinical picture. «Acute» and «developing» subtypes of PMDS predominantly developed in schizoaffective psychosis and bipolar disorder; the «chronified» subtype and the «double mania» subtype were more often observed within the framework of the schizoaffective variant of paroxysmal-progressive schizophrenia. Conclusion. The clinical and dynamic structure of PMDS is heterogeneous and differs in psychopathological structure, as well as in the level of stability of symptoms and characteristics of its course. The developed clinical typology of PMDS is prognostically significant and provides information about the further dynamics of the disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (6) , 94-100
Basic symptoms in young female patients with depression within the framework of schizophrenia and affective spectrum disorders
Objective. To investigate the structure and severity of basic symptoms in young female patients with endogenous depression. Material and methods. One hundred and nineteen female patients, aged from 16 to 26 years, were examined. Three groups were identified: patients meeting the criteria of high risk of psychosis (51 patients, mean age 18.55±3.84 years), patients not meeting the criteria of high risk of psychosis(48 patients, mean age 20.12±3.84 years), patients with postpsychotic depression (20 patients, mean age 21.8±4.5 years). The main method of the study was the application of COGDIS (Cognitive Distortions) and COPER (Cognitive-perceptual baseline symptoms) criteria. Results. The baseline symptoms criteria were met by 83.3% of depressed patients without psychosis risk symptoms (mean severity score 24.0±14.7), 96% of depressed patients with high psychosis risk symptoms (38.1±15.9 points), and 50% of patients with postpsychotic depression (15.3±12.9 points). COGDIS criteria were met by 62.5% of depressed patients without psychosis risk symptoms (16.2±10.1 points), 68.6% of depressed patients with high psychosis risk symptoms (22.3±9.6 points), and 25% of patients with postpsychotic depression (9.2±8.4 points). The COPER criteria were met by 77.5% of patients with depression without psychosis risk symptoms (16.2±10.3 points), 92.2% of patients with depression at high risk of psychosis (28.4±14.0 points), and 50% of patients with postpsychotic depression (8.9±9.7 points). Conclusions. The group with post schizophrenic depression was characterized by lower basic symptom scale scores and percentage of eligible patients. Basic symptoms were common in a group of young female patients with depression who did not meet high-risk criteria. The score differentiates the high-risk group from the group of patients without risk symptoms.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (6) , 94-100
Basic symptoms in young female patients with depression within the framework of schizophrenia and affective spectrum disorders
Objective. To investigate the structure and severity of basic symptoms in young female patients with endogenous depression. Material and methods. One hundred and nineteen female patients, aged from 16 to 26 years, were examined. Three groups were identified: patients meeting the criteria of high risk of psychosis (51 patients, mean age 18.55±3.84 years), patients not meeting the criteria of high risk of psychosis(48 patients, mean age 20.12±3.84 years), patients with postpsychotic depression (20 patients, mean age 21.8±4.5 years). The main method of the study was the application of COGDIS (Cognitive Distortions) and COPER (Cognitive-perceptual baseline symptoms) criteria. Results. The baseline symptoms criteria were met by 83.3% of depressed patients without psychosis risk symptoms (mean severity score 24.0±14.7), 96% of depressed patients with high psychosis risk symptoms (38.1±15.9 points), and 50% of patients with postpsychotic depression (15.3±12.9 points). COGDIS criteria were met by 62.5% of depressed patients without psychosis risk symptoms (16.2±10.1 points), 68.6% of depressed patients with high psychosis risk symptoms (22.3±9.6 points), and 25% of patients with postpsychotic depression (9.2±8.4 points). The COPER criteria were met by 77.5% of patients with depression without psychosis risk symptoms (16.2±10.3 points), 92.2% of patients with depression at high risk of psychosis (28.4±14.0 points), and 50% of patients with postpsychotic depression (8.9±9.7 points). Conclusions. The group with post schizophrenic depression was characterized by lower basic symptom scale scores and percentage of eligible patients. Basic symptoms were common in a group of young female patients with depression who did not meet high-risk criteria. The score differentiates the high-risk group from the group of patients without risk symptoms.
- 26 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (3) , 130-136
Functional hypercortisolism in mental disorder — association with psychopathological manifestations and course of the disease
The article presents a case of a long-term mental disorder in a 35-year-old woman with a persistent laboratory-confirmed increase in cortisol levels, without clinical manifestations of hypercortisolism. The first signs of mental illness appeared at the age of 14; over the past 8 years, the disease has been continuous and manifests itself in the form of a predominantly depressive state with increasing severity and complication of symptoms. Throughout all the years of the disease, active psychopharmacotherapy was carried out, combinations of antidepressants with antipsychotics and mood stabilizers were used, but no pronounced effect was achieved. Inpatient treatment in the clinic of the Mental Health Research Center for 5 months using several methods of enhancing antidepressant therapy had a good therapeutic effect and made it possible to achieve complete remission of the disease. There was a normalization of laboratory parameters of cortisol along with a decrease in the severity of pathopsychological symptoms, which indicates the genesis of hypercortisolism secondary to mental illness and its functional nature. It is assumed that hypercortisolism in this patient contributed to the formation of atypical clinical symptoms and resistance to antidepressant therapy. The discussion substantiates the need to consult a psychiatrist in case of persistent hypercortisolism in the absence of clinical manifestations of Cushing’s syndrome. The detection of persistent hypercortisolism in patients with depression determines the advisability of active therapy using several tactics to enhance the effect of antidepressants.
- 26 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (3) , 130-136
Functional hypercortisolism in mental disorder — association with psychopathological manifestations and course of the disease
The article presents a case of a long-term mental disorder in a 35-year-old woman with a persistent laboratory-confirmed increase in cortisol levels, without clinical manifestations of hypercortisolism. The first signs of mental illness appeared at the age of 14; over the past 8 years, the disease has been continuous and manifests itself in the form of a predominantly depressive state with increasing severity and complication of symptoms. Throughout all the years of the disease, active psychopharmacotherapy was carried out, combinations of antidepressants with antipsychotics and mood stabilizers were used, but no pronounced effect was achieved. Inpatient treatment in the clinic of the Mental Health Research Center for 5 months using several methods of enhancing antidepressant therapy had a good therapeutic effect and made it possible to achieve complete remission of the disease. There was a normalization of laboratory parameters of cortisol along with a decrease in the severity of pathopsychological symptoms, which indicates the genesis of hypercortisolism secondary to mental illness and its functional nature. It is assumed that hypercortisolism in this patient contributed to the formation of atypical clinical symptoms and resistance to antidepressant therapy. The discussion substantiates the need to consult a psychiatrist in case of persistent hypercortisolism in the absence of clinical manifestations of Cushing’s syndrome. The detection of persistent hypercortisolism in patients with depression determines the advisability of active therapy using several tactics to enhance the effect of antidepressants.
- 21 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (11) , 68-73
Depersonalization depression in young female patients
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить особенности психопатологической структуры деперсонализационных депрессий у молодых женщин, а также особенности несуицидального аутоагрессивного и суицидального поведения в этих состояниях. МАТЕРИАЛ И МЕТОДЫ Клинико-психопатологически исследованы 36 пациенток молодого возраста (16—25 лет), страдавших эндогенными депрессиями (F31.3-4; F34.0; F21.3-4+F31.3-4; F60.X+F31.3-4) с доминированием в их клинической картине деперсонализационных расстройств, представленных в виде ауто-, алло- и соматопсихических форм последних или их сочетания. РЕЗУЛЬТАТЫ Деперсонализационные депрессии у пациенток молодого возраста характеризуются: доминированием проявлений чувственной («истерической») формы деперсонализации (83,3%; n=30); близостью феномена соматопсихической деперсонализации (77,8%; n=28) к проявлениям дисморфофобических расстройств; своеобразием проявлений дереализации в виде чувства «наигранности, подстроенности» окружающего; редкостью проявлений психической анестезии; выраженным полиморфизмом клинической картины с коморбидными обсессивно-компульсивными, истеро-конверсионными, сенестопатическими, дисморфофобическими и аттенуированными психотическими расстройствами; высоким суицидальным риском (83,3%; n=30) с преобладанием планируемых суицидальных попыток над импульсивными; значительной частотой и разнообразием несуицидальных самоповреждений с доминированием «деперсонализационных» мотивов их совершения. ЗАКЛЮЧЕНИЕ Деперсонализационные депрессии у пациенток молодого возраста характеризуются клиническим своеобразием, проявляющимся как в картине собственно деперсонализационной симптоматики и спектре коморбидных нарушений, так и в особенностях мотивов и методов совершаемых больными суицидальных попыток и несуицидальных самоповреждений.
- 21 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (11) , 68-73
Depersonalization depression in young female patients
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить особенности психопатологической структуры деперсонализационных депрессий у молодых женщин, а также особенности несуицидального аутоагрессивного и суицидального поведения в этих состояниях. МАТЕРИАЛ И МЕТОДЫ Клинико-психопатологически исследованы 36 пациенток молодого возраста (16—25 лет), страдавших эндогенными депрессиями (F31.3-4; F34.0; F21.3-4+F31.3-4; F60.X+F31.3-4) с доминированием в их клинической картине деперсонализационных расстройств, представленных в виде ауто-, алло- и соматопсихических форм последних или их сочетания. РЕЗУЛЬТАТЫ Деперсонализационные депрессии у пациенток молодого возраста характеризуются: доминированием проявлений чувственной («истерической») формы деперсонализации (83,3%; n=30); близостью феномена соматопсихической деперсонализации (77,8%; n=28) к проявлениям дисморфофобических расстройств; своеобразием проявлений дереализации в виде чувства «наигранности, подстроенности» окружающего; редкостью проявлений психической анестезии; выраженным полиморфизмом клинической картины с коморбидными обсессивно-компульсивными, истеро-конверсионными, сенестопатическими, дисморфофобическими и аттенуированными психотическими расстройствами; высоким суицидальным риском (83,3%; n=30) с преобладанием планируемых суицидальных попыток над импульсивными; значительной частотой и разнообразием несуицидальных самоповреждений с доминированием «деперсонализационных» мотивов их совершения. ЗАКЛЮЧЕНИЕ Деперсонализационные депрессии у пациенток молодого возраста характеризуются клиническим своеобразием, проявляющимся как в картине собственно деперсонализационной симптоматики и спектре коморбидных нарушений, так и в особенностях мотивов и методов совершаемых больными суицидальных попыток и несуицидальных самоповреждений.
- 21 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (11) , 46-54
Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice
Objective. To evaluate the effectiveness and safety of escitalopram in the form of oral dispersible tablets (Elicea Q-Tab) in real-life clinical practice in patients with depressive and anxiety disorders. Material and methods. The study included 1.892 outpatient patients, 1.860 of whom completed participation in accordance with the protocol and entered the statistical analysis. Most patients were diagnosed with depressive and anxiety disorders of varying severity, as a rule, these diagnoses were established for the first time. The drug was most often prescribed at a dosage of 10 mg/day. The patients were monitored for 90 days and at each of the 3 visits, scales were used to assess the clinical condition (CGI-S and CGI-I), scales «Interaction with people, maintaining relationships (social functioning)» and «Availability of work, task completion, school attendance (professional functioning)», scales satisfaction with the convenience of admission/appointment and the effectiveness of treatment, various indicators of quality of life (autonomy, social and professional functioning, hobbies and hobbies), as well as the severity of cognitive disorders were measured. Results. Patients treated with escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) showed an improvement in their clinical condition (a decrease in CGI—S scores from 3.65 at visit 1 to 2.63 by visit 3, by 28%; a decrease in CGI—I scores from 2.39 at visit 1 to 1.57 to visit 3, by 34%), as well as improving the quality of life, social (from 2.74 points on 1 visit to 4.32 on 2 visits, by 58%) and professional functioning (from 2.81 on 1 visit to 4.35 on 2 visits, by 55%), the level of concentration (from 3.28 points on 1 visit up to 4.5 on 3 visits, by 37%). Doctors and patients noted high satisfaction with the effectiveness and convenience of using the drug, the frequency of adverse events was low. Conclusion. The study showed that escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) is an efficient and safe treatment for depressive and anxiety disorders in real-world clinical settings. Patients and physicians have evaluated the drug positively and it can be considered as an effective agent in psychiatric practice.
- 21 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (11) , 46-54
Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice
Objective. To evaluate the effectiveness and safety of escitalopram in the form of oral dispersible tablets (Elicea Q-Tab) in real-life clinical practice in patients with depressive and anxiety disorders. Material and methods. The study included 1.892 outpatient patients, 1.860 of whom completed participation in accordance with the protocol and entered the statistical analysis. Most patients were diagnosed with depressive and anxiety disorders of varying severity, as a rule, these diagnoses were established for the first time. The drug was most often prescribed at a dosage of 10 mg/day. The patients were monitored for 90 days and at each of the 3 visits, scales were used to assess the clinical condition (CGI-S and CGI-I), scales «Interaction with people, maintaining relationships (social functioning)» and «Availability of work, task completion, school attendance (professional functioning)», scales satisfaction with the convenience of admission/appointment and the effectiveness of treatment, various indicators of quality of life (autonomy, social and professional functioning, hobbies and hobbies), as well as the severity of cognitive disorders were measured. Results. Patients treated with escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) showed an improvement in their clinical condition (a decrease in CGI—S scores from 3.65 at visit 1 to 2.63 by visit 3, by 28%; a decrease in CGI—I scores from 2.39 at visit 1 to 1.57 to visit 3, by 34%), as well as improving the quality of life, social (from 2.74 points on 1 visit to 4.32 on 2 visits, by 58%) and professional functioning (from 2.81 on 1 visit to 4.35 on 2 visits, by 55%), the level of concentration (from 3.28 points on 1 visit up to 4.5 on 3 visits, by 37%). Doctors and patients noted high satisfaction with the effectiveness and convenience of using the drug, the frequency of adverse events was low. Conclusion. The study showed that escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) is an efficient and safe treatment for depressive and anxiety disorders in real-world clinical settings. Patients and physicians have evaluated the drug positively and it can be considered as an effective agent in psychiatric practice.
- Open Access
- 19 June 2023
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 21 (3) , 6-19
Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study
Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identified as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efficacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efficacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efficacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efficacy in augmentation of antidepressant therapy and has a favorable tolerability profile. The maximum efficacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.
- 19 June 2023
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 21 (3) , 6-19
Open AccessUse of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study
Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identified as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efficacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efficacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efficacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efficacy in augmentation of antidepressant therapy and has a favorable tolerability profile. The maximum efficacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.